The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of gut microbiota and peri-initiation proton pump inhibitor/antibiotic exposure with outcomes of atezolizumab-bevacizumab-carboplatin-paclitaxel regimen in patients with advanced non-squamous NSCLC: Prospective phase II study (K-TAIL-201).
 
Hiroshi Wakui
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyouwa Kirin; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Takahiro Yoshizawa
Speakers' Bureau - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; MSD; Nippon Kayaku; Ono Pharmaceutical
 
Sojiro Kusumoto
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD; Taiho Pharmaceutical
 
Tsuneo Shimokawa
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Gilead Sciences (Inst); Kissei Pharmaceutical (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Hiroyuki Suzuki
No Relationships to Disclose
 
Junya Isobe
No Relationships to Disclose
 
Masahiro Shimokawa
No Relationships to Disclose
 
Ryotaro Ohkuma
No Relationships to Disclose
 
Hirotsugu Ariizumi
No Relationships to Disclose
 
Yutaro Kubota
No Relationships to Disclose
 
Kazutoshi Isobe
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo Company, Limited; Lilly; Merck Sharp & Dohme (MSD); Nippon Kayaku; Novartis; Taiho Pharmaceutical; Takeda
 
Eisuke Inoue
Consulting or Advisory Role - BiPSEE Inc.; CYBERDYNE INC.; CYBERNET SYSTEMS CO., LTD.
Speakers' Bureau - Chugai Pharma; Eisai
 
Satoshi Wada
No Relationships to Disclose
 
Hironori Sagara
Honoraria - AstraZeneca; Boehringer Ingelheim; Eisai; Gilead Sciences; GlaxoSmithKline; Insmed; Kracie Pharmaceutical; Kyorin; Novartis; Regeneron; Sanofi
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Eisai; Gilead Sciences; GlaxoSmithKline; Insmed; Kracie Pharmaceutical; Kyorin; Novartis; Regeneron; Sanofi
 
Kazuma Kishi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Speakers' Bureau - Boehringer Ingelheim
 
Shinichi Kobayashi
No Relationships to Disclose
 
Jun Araya
No Relationships to Disclose
 
Kiyoshi Yoshimura
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Kyowa Kirin
 
Takuya Tsunoda
No Relationships to Disclose
 
Atsushi Horiike
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; EP-SOGO; Kyowa Kirin International; MSD Oncology; Taiho Oncology
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD Oncology (Inst); Nihonkayaku (Inst)